Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?
作者信息
Batista Marta Vaz, Perez-Gracia José, Eiriz Inês, Gion Maria, Llombart Antonio, Braga Sofia, Cortés Javier
出版信息
Oncotarget. 2023 Jul 7;14:701-702. doi: 10.18632/oncotarget.28435.
Abstract
摘要
相似文献
1
Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?HER2阳性晚期乳腺癌脑转移的全身治疗：我们目前了解到了什么？
Oncotarget. 2023 Jul 7;14:701-702. doi: 10.18632/oncotarget.28435.
2
Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.HER2阳性乳腺癌脑转移患者全脑放疗后抗HER2治疗的生存获益。
Breast Cancer. 2016 Sep;23(5):732-9. doi: 10.1007/s12282-015-0631-x. Epub 2015 Aug 13.
3
A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis.曲妥珠单抗治疗HER2阳性且对他莫昔芬耐药的脑转移乳腺癌疗效的回顾性研究
BioDrugs. 2016 Feb;30(1):33-40. doi: 10.1007/s40259-015-0156-z.
4
HER2-positive metastatic breast cancer: a comprehensive review.人表皮生长因子受体 2 阳性转移性乳腺癌：全面综述。
Clin Adv Hematol Oncol. 2021 Jan;19(1):40-50.
5
HER2-positive metastatic breast cancer: a changing scenario.人表皮生长因子受体2阳性转移性乳腺癌：不断变化的情况。
Crit Rev Oncol Hematol. 2015 Jul;95(1):78-87. doi: 10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20.
6
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.曲妥珠单抗摄取及其与HER2阳性乳腺癌脑转移动物模型疗效的关系。
Breast Cancer Res Treat. 2017 Aug;164(3):581-591. doi: 10.1007/s10549-017-4279-4. Epub 2017 May 10.
7
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.阿法替尼单药或联合长春瑞滨与曲妥珠单抗、拉帕替尼或两者治疗后出现进展性脑转移的 HER2 阳性乳腺癌患者的研究者选择治疗方案：一项随机、开放标签、多中心、Ⅱ期临床试验（LUX-Breast 3）。
Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17.
8
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?针对脑转移的新型抗 HER2 药物：组织学上的通用武器？
Breast Cancer Res Treat. 2021 Feb;185(3):879-881. doi: 10.1007/s10549-020-05982-y. Epub 2020 Oct 30.
9
Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.帕妥珠单抗和曲妥珠单抗治疗HER2阳性脑转移乳腺癌的显著长期疗效
In Vivo. 2018 Jul-Aug;32(4):839-842. doi: 10.21873/invivo.11317.
10
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.HER2阳性乳腺癌发生脑转移患者的预后因素：一项多中心回顾性分析。
Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21.
引用本文的文献
1
HER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain Metastasis.HER2阳性乳腺癌——脑转移的当前治疗管理及新治疗方法
Biomedicines. 2025 May 9;13(5):1153. doi: 10.3390/biomedicines13051153.
2
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌脑转移瘤：系统评价和荟萃分析。
ESMO Open. 2024 Feb;9(2):102233. doi: 10.1016/j.esmoop.2024.102233. Epub 2024 Feb 5.
本文引用的文献
1
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
2
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌伴中枢神经系统转移患者：DEBBRAH 试验。
Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144.
3
Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study.吡咯替尼对比曲妥珠单抗-恩杂鲁胺用于既往接受过曲妥珠单抗和拉帕替尼治疗的HER2阳性转移性乳腺癌：一项真实世界研究
Ann Transl Med. 2021 Jan;9(2):103. doi: 10.21037/atm-20-4054.
4
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.奈拉替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌：NALA Ⅲ期临床试验。
J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17.
5
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.曲妥珠单抗-美坦新偶联物（T-DM1）治疗人表皮生长因子受体 2 阳性转移性乳腺癌伴脑转移患者：来自 KAMILLA 研究队列 1 的探索性最终分析，一项单臂 IIIb 期临床研究。
Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5.
6
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.在 HER2CLIMB 试验中，曲妥珠单抗联合卡培他滨治疗既往治疗的 HER2 阳性乳腺癌伴脑转移的颅内疗效和生存。
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
7
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌的治疗
N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
8
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.曲妥珠单抗-恩杂鲁胺（T-DM1）对比拉帕替尼加卡培他滨治疗HER2阳性转移性乳腺癌合并中枢神经系统转移患者：EMILIA研究的一项回顾性探索性分析
Ann Oncol. 2015 Jan;26(1):113-119. doi: 10.1093/annonc/mdu486. Epub 2014 Oct 29.
Zotero 插件